Neurocrine Biosciences Inc (NBIX)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 249,700 | 154,500 | 89,600 | 407,300 | 37,000 |
| Total stockholders’ equity | US$ in thousands | 2,232,000 | 1,707,800 | 1,374,000 | 1,126,200 | 636,900 |
| ROE | 11.19% | 9.05% | 6.52% | 36.17% | 5.81% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $249,700K ÷ $2,232,000K
= 11.19%
Neurocrine Biosciences, Inc.'s return on equity (ROE) has fluctuated over the past five years. In 2023, the ROE was 11.19%, showing an increase from the previous year's 9.05%. This improvement indicates that the company generated a higher profit relative to its shareholder equity in 2023.
Compared to the lower ROEs in 2021 and 2019, the most recent ROE suggests an upward trend in the company's profitability and efficiency in the utilization of shareholder investments. However, the ROE of 36.17% in 2020 stands out as significantly higher, indicating exceptional profitability that year.
The fluctuation in ROE could be attributed to various factors such as changes in net income, total equity, or financial leverage. Investors and analysts may further investigate the underlying reasons behind these fluctuations to gain a better understanding of Neurocrine Biosciences, Inc.'s financial performance and future prospects.
Peer comparison
Dec 31, 2023